Esperion Therapeutics (ESPR) Current Leases (2019 - 2026)

Esperion Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• Quarterly Current Leases fell 39.79% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 39.79% YoY) and the FY2025 annual result came in at $2.1 million, down 23.31% from the prior year.
• Current Leases was $1.7 million for Q1 2026 at Esperion Therapeutics, down from $2.1 million in the prior quarter.
• Across five years, Current Leases topped out at $2.8 million in Q1 2025 and bottomed at $305000.0 in Q1 2023.
• A 5-year average of $1.7 million and a median of $1.7 million in 2026 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2023 — Current Leases tumbled 74.94% — and 2024, when it soared 732.46%.
• Esperion Therapeutics' Current Leases stood at $384000.0 in 2022, then soared by 304.43% to $1.6 million in 2023, then jumped by 76.5% to $2.7 million in 2024, then fell by 23.31% to $2.1 million in 2025, then declined by 19.17% to $1.7 million in 2026.
• Business Quant data shows ESPR's Current Leases at $1.7 million in Q1 2026, $2.1 million in Q4 2025, and $2.4 million in Q3 2025.